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ABSTRACT. The glutathione S-transferase (GST) family comprises 
phase-II cellular detoxification enzymes that catalyze the conjugation 
of chemotherapy drugs to glutathione and act on the apoptotic pathway. 
The aim of this study was to determine whether polymorphisms of the 
GSTT1, GSTM1, and GSTP1 genes are associated with different rates of 
overall survival (OS) and disease-free survival (DFS) after neoadjuvant 
chemotherapy in the management of locally advanced breast cancer, 
using either simple or combined analyses, and in relation to the post-
therapy axillary lymph node status. Forty women with invasive ductal 
carcinoma of the breast submitted to neoadjuvant chemotherapy with 
5-fluorouracil, epirubicin, and cyclophosphamide were genotyped for 
GSTT1, GSTM1, and GSTP1. Comparisons were performed for the 
three genes, either isolated or in pairs, in polymorphic or wild-type 
combinations. Finally, the OS and DFS of patients were analyzed with 
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respect to axillary lymph node status and with respect to wild-type or 
polymorphic presentations of each gene. No statistically significant 
difference in OS and DFS was evident between women with wild-
type or polymorphic forms of the genes, either isolated or in pairs, 
after neoadjuvant chemotherapy. By contrast, after treatment, lymph 
node-negative women had better OS and DFS only in the presence of 
polymorphisms of GSTP1, and improved DFS only in the presence of 
the polymorphic types of GSTT1 and GSTM1 compared to women with 
positive lymph nodes. The presence of polymorphic forms of GSTP1, 
GSTM1, and GSTT1 was crucial to conferring better OS and DFS 
among women with negative axillary lymph nodes.
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INTRODUCTION
Breast cancer (BC) is the most prevalent gynecological neoplasia in women world-
wide, with an estimated 207,090 new cases and 39,840 deaths in 2010 for the United States 
alone (Jemal et al., 2010). Since the first studies in solid tumors, the role of adjuvant chemo-
therapy has become increasingly important in the treatment of locally advanced breast tumors 
(Shapiro and Fugmann, 1957).
Advanced stages of the disease and drug resistance mechanisms represent the greatest 
barriers to effective treatment of BC (Leonessa and Clarke, 2003). Consequently, there have 
been major shifts in the paradigms for managing BC, leading to increasingly multi-disciplin-
ary approaches.
Drawing on knowledge of the cell cycle and mechanisms of action of the chemothera-
peutic drugs used in BC, a multi-drug treatment strategy has been adopted that acts at different 
phases of the cell cycle, conferring greater patient survival and longer disease-free periods 
after surgical treatment (Fisher et al., 1968). However, evidence also shows that women at the 
same clinical stage of BC react differently to the same treatment, with some groups presenting 
with disease progression. The main reasons for failure of chemotherapy in cancer patients are 
disease spread and drug-resistance mechanisms (Terek et al., 2003; Jemal et al., 2010). Bio-
chemical and molecular aspects of this resistance process have been described in a number of 
studies, implicating a significant contribution of enzymes encoded by genes of the glutathione 
S-transferase family (GSTs) (Hayes and Pulford, 1995; O’Brien and Tew, 1996; Burg and 
Mulder, 2002; Townsend and Tew, 2003a,b; L’Ecuyer et al., 2004).
Theta class proteins are encoded by two genes (GSTT1 and GSTT2) that are located on 
chromosome 22. The presence of the GSTT1 null form, which does not produce the enzymes 
purifying cellular metabolism, has been associated with enhanced responses to chemotherapy 
in patients with BC (Khedhaier et al., 2003).
Proteins belonging to the Mu class are encoded by a group of genes located on chromo-
some 1 (GSTM 1-5). The GSTM1 null genotype is unable to produce the catalyzing enzymes 
necessary for the process of conjugation with glutathione. In addition, individuals with this 
null genotype do not synthesize the proteins that can bind proteins from the ASK1 pathway, 
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which are required for inhibition of this apoptotic pathway (Figure 1). These polymorphic 
forms are associated with improved responses to some classes of chemotherapeutic drugs that 
are currently used against a range of cancer types (Ambrosone et al., 2001; Cho et al., 2001; 
Townsend and Tew, 2003a,b; Khedhaier et al., 2003; McIlwain et al., 2006).
The Pi class of GST proteins comprises only a single protein that is encoded by a gene 
located on chromosome 11 called GSTP1. With regards to its role in cellular protection, this 
gene is relatively more associated with the apoptotic process. However, polymorphic forms 
of GSTP1 are unable to synthesize the proteins that bind to enzymes of the JNK pathway, and 
therefore cannot inhibit this apoptotic pathway (Adler et al., 1999; Dang et al., 2005) (Figure 
1). In addition, these polymorphisms do not encode cellular detoxification enzymes.
Previous studies associating the presence of polymorphic forms of GST genes with 
responses to cancer chemotherapy have shown conflicting results; moreover, these are gener-
ally based on inconsistent data (Riddick et al., 2005). This prompted our group to investigate 
overall survival (OS) and disease-free survival (DFS) in women with invasive ductal carci-
noma of the breast (stages II and III) in relation to the presence of the polymorphisms GSTT1/
GSTT1 “null”, GSTM1/GSTM1 “null”, and GSTP1 Ile105Ile/ GSTP1 Ile105Val.
MATERIAL AND METHODS
Patients
This longitudinal prospective study, which was approved by the Research Ethics 
Committee of Santa Casa de São Paulo Hospital, involved a randomized sample of 52 women 
with clinically confirmed breast cancer who were seen at the Department of Obstetrics and 
Gynecology of Santa Casa de São Paulo Hospital, Brazil. Subjects were recruited between 
July 2004 and July 2006, and all patients underwent clinical, laboratory, and radiological 
follow-up up to December 2009. The study inclusion criteria were as follows: patients aged 
between 30 and 75 years with singular, unilateral, primary neoplasia of the breast (assessed by 
mammography, ultrasonography, and magnetic resonance imaging of the breast) with UICC 
stage II or III invasive ductal histology in the absence of cardiopathy.
Of the initial 52 patients recruited, 12 were excluded: one patient was diagnosed with 
granulomatous mastitis, one patient presented morbid obesity precluding the magnetic reso-
nance imaging examination, three patients had metastatic tumors, six patients were diagnosed 
with invasive lobular carcinoma, and one patient was excluded because her DNA sample 
presented degradation. This resulted in a final group of 40 patients, all of whom met the inclu-
sion criteria and signed an informed consent form. Patients were submitted to skin tattooing 
to mark the clinical limits of the initial tumors prior to starting chemotherapy. Chemotherapy 
was performed in three preoperative cycles, interspersed by 21-day intervals, using the 5-flu-
orouracil-epirubicin-cyclophosphamide scheme. Patients were assessed clinically according 
to the criteria adopted by the Response Evaluation Criteria in Solid Tumors Group (RECIST) 
(Therasse et al., 2000). Subjects presenting greater than or equal to 30% reduction in tumor 
diameter upon clinical measurements were considered responders, whereas those showing a 
less than 30% reduction in tumor diameter, or presenting disease stability or progression were 
classified as non-responders. Upon completing three primary chemotherapy cycles, patients 
were submitted to operative therapy based on radical or conservative surgery. Follow-up en-
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tailed review of the patients’ medical records up to December 2009.
DNA extraction
A 5-mL venous blood sample was taken from the peripheral antecubital ulnar vein and 
placed in a sterile vial containing 10% edetic acid (EDTA) as an anti-coagulant. DNA extrac-
tion was performed using the salting-out method proposed by Lahiri and Nurberger (1991) as 
modified by Cavalli et al. (1996) and Salazar et al. (1998).
Multiplex polymerase chain reaction (PCR) of GSTT1 and GSTM1 and enzymatic 
digestion PCR of polymorphic fragments of GSTP1
The genotypes of GSTM1 and GSTT1 were determined by co-amplification using 
multiplex PCR, with the β-globin gene as the internal control, as described by Wilson et al. 
(2000). The products related to the GSTP1 gene were obtained by PCR-restriction fragment 
length polymorphism (RFLP). The amplified product was then digested with the Alw26I 
restriction enzyme (New England Biolabs; Ipswich, MA, USA), yielding 91- and 86-bp 
fragments for the homozygous GSTP1105Val genotype, 176-, 91-, and 86-bp fragments for 
the heterozygous GSTP1Ile105Val genotype, and a single 176-bp fragment for the wild-type 
GSTP1105Ile genotype.
Statistical analysis
Statistical analyses were performed using the Microsoft Excel program version 2007 
to create the study database. Kaplan-Meier curves were applied for the determination of OS 
and DFS and chi-squared (Pearson’s or Fisher’s exact) tests of significance were employed 
with a 95% confidence interval.
RESULTS
In the present study, the mean and median age of patients assessed was 52 years. Six 
patients were classified as stage IIa, 22 as stage IIb, and 12 as stage IIIa. Out of the 40 pa-
tients studied, five (12.5%) showed a full pathological response according to RECIST criteria. 
Anatomopathological analysis revealed that 20 patients were lymph node-positive and 20 pa-
tients were lymph node-negative post-surgery; 24 (60%) were considered to be responders and 
16 (40%) were non-responders according to RECIST criteria. The mean DFS observed was 
43.8 months (range: 4.2-64.4 months) and the mean OS was 50.3 months (range: 19.3-64.6 
months). Eleven patients died during the follow-up period due to disease progression.
There was no statistically significant difference in OS and DFS between the wild-
type and polymorphic forms of GSTT1, GSTM1, and GSTP1 when analyzed either isolated 
or paired. Women with negative axilla showed a statistically significant difference in DFS 
and OS in the comparative analysis of the pathological status of lymph nodes after neoad-
juvant chemotherapy. However, women with negative axillary lymph nodes showed signifi-
cantly increased OS and DFS compared to women with positive axillary lymph nodes only 
in the presence of polymorphic forms of GSTT1, GSTP1, and GSTM1 (Figures 1 to 6).
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Figure 2. Disease-free survival in patients with positive or negative lymph nodes after neoadjuvant chemotherapy 
and surgery.
Figure 1. Overall survival in patients with positive or negative lymph nodes after neoadjuvant chemotherapy and surgery.
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Figure 3. Disease-free survival in patients with positive or negative lymph nodes after neoadjuvant chemotherapy 
and surgery among women with the polymorphic form of the GSTT1 gene.
Figure 4. Disease-free survival in patients with positive or negative lymph nodes after neoadjuvant chemotherapy 
and surgery among women with the polymorphic form of the GSTM1 gene.
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Figure 6. Overall survival in patients with positive or negative lymph nodes after neoadjuvant chemotherapy and 
surgery among women with the polymorphic form of the GSTP1 gene.
Figure 5. Disease-free survival in patients with positive or negative lymph nodes after neoadjuvant chemotherapy 
and surgery among women with the polymorphic form of the GSTP1 gene.
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DISCUSSION
The present study, which examined the three genes from the GST family that show 
associations with BC (GSTT1, GSTM1, and GSTP1), adopted two specific and unique features 
compared with previous related studies: i) a longitudinal prospective study design was employed 
to analyze OS and DFS based on molecular biology; ii) the behavior of these genes was studied 
in relation to anatomopathological lymph node status as a prognostic factor for OS and DFS.
Numerous studies have sought to establish a relationship between the response to 
chemotherapy and the action of cellular survival mechanisms, and to ascertain the specific 
impact of this cellular process on the prognosis of cancer patients. This process is related to 
the action of proteins that enable the efflux of drugs by cellular detoxification mechanisms and 
changes in apoptotic pathways, both of which are promoted by the genes in the GST family 
investigated in the present study.
The NSABP B18 protocol appeared to confirm an absence of any effect of neoadjuvant 
chemotherapy on OS or DFS. However, further analyses of these patients showed a tendency 
toward benefits in individuals younger than 50 years. Furthermore, the presence of a full patho-
logical response is a prognostic factor that predicts enhanced rates of survival in patients under-
going neoadjuvant chemotherapy, especially when post-treatment lymph node status reveals the 
absence of metastases (Fisher et al., 1998; Wolmark et al., 2001; Rastogi et al., 2008).
In the first phase of the study, a full response was observed in five patients (12.5%) 
(Oliveira et al. 2010), whereas here, in the second phase, the absence of lymph node invasion 
after chemotherapy was found to be a determinant of longer OS and DFS (P = 0.039 and P = 
0.008). Besides determining the loco-regional response after neo-adjuvant chemotherapy and 
isolated survival assessment in lymph node-negative women, another objective of this study 
was to ascertain whether the mechanism of action of the polymorphic forms of the genes stud-
ied exerted an effect on survival among these women when analyzed separately, or whether 
they correlated with the pathological status of lymph nodes after chemotherapy and surgery.
In our previous studies, the clinical response to neoadjuvant chemotherapy was shown 
to be independent of the types of polymorphisms of the MDR-1 (Rodrigues et al., 2008) gene 
and GSTT1, GSTM1, and GSTP1 (Oliveira et al., 2010).
Follow-up of this patient cohort showed that the presence of wild-type or polymorphic 
forms of the GSTT1, GSTM1, and GSTP1 genes, either alone or in pairs, had no impact on OS 
and DFS. In contrast with our findings, other authors have observed enhanced survival rates 
among women with BC who are carriers of the polymorphic form of these genes (Sweeney et 
al., 2000; Ambrosone et al., 2001).
Corroborating the findings of previous reports showing that lymph node-negative 
women have greater OS and DFS after chemotherapy (Fisher et al., 1998; Wolmark et al., 
2001; Rastogi et al., 2008), our data confirmed that the absence of neoplastic invasion of the 
lymph nodes after chemotherapy was a determinant of greater OS and DFS when analyzed 
separately (P = 0.039 and P = 0.008). However, our results indicated that the significant dif-
ference in DFS in node-negative women only occurred in carriers of the polymorphic forms 
of GSTT1 (P = 0.028) and GSTM1 (P = 0.002), whereas those with the polymorphic form of 
GSTP1 had both greater DFS (P = 0.008) and OS (P = 0.006). Interestingly, the same improved 
survival rates were not evident when histopathological assessment of lymph nodes, even when 
negative, involved wild-type forms of the same genes.
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In line with the present study of BC, previous investigations of Hodgkin’s lymphoma, 
ovarian cancer, colorectal cancer, and even BC have also found the same improved survival 
rates when lymph node status was associated with polymorphic forms of GSTT1, GSTM1, 
and GSTP1 (Khedhaier et al., 2003; Huang et al., 2003; Hohaus et al., 2005; DeMichele et al., 
2005; Beeghly et al., 2006; Holley et al., 2006; Kweekel et al., 2008; Kolwijck et al., 2009; 
Jones et al., 2009;  Khrunin et al., 2010).
Based on these results and the concepts outlined, we observed that the presence of the 
wild-type genotype of GSTM1, GSTT1, and GSTP1 had a negative impact on both DFS and 
OS in the lymph node-negative patient group. This association indicates that the polymorphic 
genotypes of these same genes promote a greater sensitivity to chemotherapy, which is most 
likely due to the differential role of the polymorphic forms of genes from the GST family in the 
process of apoptosis and cellular detoxification, especially the polymorphic form of GSTP1.
The presence of polymorphic forms of GSTP1, GSTM1, and GSTT1 was crucial to 
improve OS and DFS among women with negative axillary lymph nodes.
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